Poniard Pharmaceuticals : Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit

April 23, 2008 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that final efficacy results from its Phase 2 clinical trial of picoplatin confirming previously announced interim results showing a survival benefit in patients with recurrent small cell lung cancer (SCLC) who have failed prior platinum-containing first-line chemotherapy or who have progressed within six months of first-line therapy. The median overall survival rate was 27 weeks and both this efficacy and the safety profile compares favorably with current medical treatments which often include palliative best supportive care. Best supportive care has been shown previously to have a median overall survival of 14 weeks and is the comparator arm for the ongoing randomized Phase 3 trial to evaluate picoplatin treatment in this patient setting. The final data were presented during a poster discussion session at the 1st European Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO)... Poniard's Press Release -

Poniard Pharmaceuticals : Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin

March 26, 2008 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced an agreement with W. C. Heraeus GmbH for the commercial manufacture and supply of picoplatin active pharmaceutical ingredient (API). Poniard is investigating picoplatin, the Company's lead product candidate, in four clinical trials, including the ongoing pivotal Phase 3 trial in small cell lung cancer, and is developing picoplatin as a potential new platform product for the treatment of solid tumors... Poniard's Press Rlease -

Poniard Pharmaceuticals : Additional data presentation on picoplatin overcoming platinum resistance in small cell lung cancer

March 19, 2008 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that preliminary data from a Phase 1 trial of an oral formulation of picoplatin in patients with solid tumors will be presented at the 2008 American Association for Cancer Research meeting to be held from April 12-16 in San Diego, CA. In addition, preclinical data of picoplatin overcoming platinum resistant small cell lung cancer cells in platinum resistant cell lines will also be presented at a separate poster presentation... Poniard's Press Release -

Poniard Pharmaceuticals, Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer

Oct 17, 2007 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that its lead product candidate, picoplatin, has been granted orphan medicinal product* designation for the treatment of small cell lung cancer (SCLC) by the European Commission. This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA)... Poniard Pharmaceuticals' Press Release-

Poniard Pharmaceuticals Picoplatin for Treatment of Small Cell Lung Cancer

Sept 05, 2007 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) : it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer (SCLC)... Read the Poniard Pharmaceuticals' Press Release -